Apollo Hospitals Enterprise Limited is India’s first and largest private integrated healthcare provider, founded in 1983 by Dr. Prathap C. Reddy. Headquartered in Chennai, it operates across the healthcare value chain—including hospitals, pharmacies, diagnostics, primary care clinics, telemedicine (Ask Apollo), and digital health platforms. With over 10,000 beds across 73 hospitals and a strong presence in tier-1 and tier-2 cities, Apollo has become synonymous with quality healthcare in India. As of January 2026, the company is delivering robust profit growth, expanding its digital ecosystem, and benefiting from rising healthcare spending. This article provides a data-driven outlook on the Apollo Hospitals share price target 2026–2030.
Apollo Hospitals: Company Overview
- Founded: 1983
- Chairman: Dr. Prathap C. Reddy
- Managing Director: Ms. Preetha Reddy
- NSE Symbol: APOLLOHOSP
- Core Business Segments:
- Hospital Services (52%)
- Pharmacy & Retail Health (25%)
- Diagnostics & Primary Care (15%)
- Digital Health & Telemedicine (8%)
- Market Position: #1 private hospital chain in India; part of Nifty 50 and BSE Sensex
Apollo Hospitals recently received NSE approval for the demerger of its pharmacy and digital health businesses—expected to unlock shareholder value and sharpen strategic focus.
Apollo Hospitals: Key Financial Snapshot
| Metric | Value |
|---|---|
| Current Share Price | ₹7,240 |
| Market Capitalization | ₹1,04,078 Cr |
| No. of Shares Outstanding | 14.38 Cr |
| 52-Week High / Low | ₹8,099 / ₹6,001 |
| P/E Ratio (TTM) | 74.25 |
| P/B Ratio | 11.17 |
| EPS (TTM) | ₹97.49 |
| Book Value (TTM) | ₹647.84 |
| ROE | 15.77% |
| ROCE | 19.25% |
| Dividend Yield | 0.26% |
| Face Value | ₹5 |
| Cash | ₹594.10 Cr |
| Debt | ₹1,783.20 Cr |
| Promoter Holding | 28.02% |
| Sales Growth (YoY) | 12.76% |
| Profit Growth (YoY) | 28.28% |
Apollo Hospitals Share Price Target Forecast (2026–2030)
| Year | Target Price Range (₹) |
|---|---|
| 2026 | ₹7,600 – ₹8,400 |
| 2027 | ₹8,100 – ₹9,100 |
| 2028 | ₹8,600 – ₹9,900 |
| 2029 | ₹9,100 – ₹10,800 |
| 2030 | ₹9,600 – ₹11,800 |
Apollo Hospitals Share Price Target 2026
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2026 | ₹7,600 | ₹8,400 |
Apollo Hospitals reported 28.28% YoY profit growth in FY2025, driven by strong occupancy rates, expansion in diagnostics, and margin improvement in hospital operations. With ROCE of 19.25% and ROE of 15.77%, the company demonstrates capital efficiency. Trading at a P/E of 74.25x and P/B of 11.17x, the stock reflects a premium valuation typical of high-quality healthcare leaders. A 2026 target range of ₹7,600–₹8,400 assumes continued execution and no major regulatory disruptions.
Apollo Hospitals Share Price Target 2027
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2027 | ₹8,100 | ₹9,100 |
If the company sustains 20–25% earnings growth and benefits from demerger clarity, EPS could reach ₹105–₹112 by FY27. Assuming a P/E of 75–78x, the 2027 target range of ₹8,100–₹9,100 is justified.
Apollo Hospitals Share Price Target 2028
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2028 | ₹8,600 | ₹9,900 |
By 2028, benefits from digital health monetization, new hospital launches (e.g., Delhi NCR, Bengaluru), and pharmacy scale-up should reflect in margins. A P/E of 78–80x on projected EPS of ₹110–₹120 supports the ₹8,600–₹9,900 band.
Apollo Hospitals Share Price Target 2029
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2029 | ₹9,100 | ₹10,800 |
Long-term tailwinds include India’s rising healthcare spend (projected to reach 3.5% of GDP by 2030), medical tourism, and insurance penetration. If competition doesn’t erode pricing, EPS could reach ₹115–₹128 by FY29. At a P/E of 80–82x, the 2029 target is ₹9,100–₹10,800.
Apollo Hospitals Share Price Target 2030
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2030 | ₹9,600 | ₹11,800 |
Over a five-year horizon, Apollo’s appeal lies in healthcare leadership + digital integration—not just volume. If ROE holds above 15% and dividends grow consistently, investor confidence will strengthen. A terminal P/E of 82–85x on FY30 EPS (~₹118–₹135) justifies the ₹9,600–₹11,800 range.
Apollo Hospitals: Shareholding Pattern
| Category | Holding (%) |
|---|---|
| Foreign Institutional Investors (FII) | 43.54% |
| Domestic Institutional Investors (DII) | 21.74% |
| Promoters | 28.02% |
| Public & Others | 6.71% |
High institutional ownership (65.28%) ensures liquidity and analyst coverage. Promoter holding remains stable despite recent stake sales.
Apollo Hospitals: Strengths vs Risks
Strengths:
- Market leader in private healthcare with national scale
- Strong brand trust and clinical excellence
- Integrated model (hospitals + pharmacy + digital) creates moat
- Consistent 28%+ profit CAGR over 5 years
Risks:
- Very high P/E leaves little room for execution misses
- Low dividend yield (0.26%) limits income appeal
- Regulatory risks in hospital pricing and drug margins
- Contingent liabilities of ₹1,200 Cr require monitoring
Investment Suitability
| Factor | Assessment |
|---|---|
| Risk Profile | Moderate to High |
| Ideal Time Horizon | 5+ years |
| Volatility | Lower than market average (Nifty 50 constituent) |
| Dividend/Income Potential | Minimal (0.26% yield) |
| Best For | Quality-focused investors betting on India’s healthcare revolution |
FAQs
Is Apollo Hospital inthe Nifty 50?
Yes. Apollo Hospitals is a constituent of the Nifty 50 index, reflecting its large-cap status and market importance.
What is the promoter share of Apollo Hospitals?
Promoter holding is 28.02% as of January 2026. This has reduced slightly due to recent open market sales, but remains strategically significant.
Who is the owner of Apollo Hospitals Enterprise Limited?
The Reddy family—led by founder Dr. Prathap C. Reddy and his daughters Preetha, Shobana, and Suneeta Reddy—is the promoter. They collectively hold 28.02% through various entities.
Is Apollo Hospital a good stock to buy?
Yes—for long-term, quality-focused investors. At a P/E of 74x and ROE of 15.8%, it trades at a justified premium. Avoid if seeking value or income.
Final Verdict
Apollo Hospitals remains India’s gold standard in private healthcare—a rare blend of scale, trust, and innovation. While not cheap, its premium valuation is backed by consistent execution and structural tailwinds.
Our Apollo Hospitals share price target 2026–2030 (₹7,600 to ₹11,800) reflects steady earnings growth, multiple stability, and sustained investor confidence. Upside is supported by healthcare demand; downside is cushioned by brand strength.
Disclaimer: Price targets are estimates based on publicly available data and sector analysis. They are not investment advice. Consult a SEBI-registered advisor before making decisions.
Sources
- Screener.in – Apollo Hospitals Consolidated Page (FY2025 + TTM)
- Moneycontrol – APOLLOHOSP Stock Quote & Financials
- Groww.in – Apollo Hospitals Stock Profile
- Finology Ticker – APOLLOHOSP Analysis & Ratios
- NSE India – Index Constituents (Nifty 50, Jan 2026)
